第3笔成交价格为15.87元，成交18.90万股，成交金额299.94万元，溢价率为-10.54%，买方营业部为机 构专用，卖方营业部为华泰证券股份有限公司南京分公司。 进一步统计，近3个月内该股累计发生45笔大宗交易，合计成交金额为1.53亿元。该股近5个交易日累计 上涨5.60%，主力资金合计净流入1837.96万元。 责任编辑：小浪快报 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月1日，奥赛康收涨0.62%，收盘价为17.74元，发生3笔大宗交易，合计成交量63.1万股，成交金额 1001.4万元。 第1笔成交价格为15.87元，成交31.50万股，成交金额499.91万元，溢价率为-10.54%，买方营业部为机 构专用，卖方营业部为华泰证券股份有限公司南京分公司。 第2笔成交价格为15.87元，成交12.70万股，成交金额201.55万元，溢价率为-10.54%，买方营业部为国 投证券股份有限公司河源分公司，卖方营业部为华泰证券股份有限公司南京分公司。 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交全额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-12-01 | 002755 | 奥赛康 | 15.87 | 31.50 | 499.91 | 机构专用 | 华泰证券股份有限 公司南京分公司 | | 2025-12-01 | 002755 | 奥塞康 | 15.87 | 12.70 | 201.55 | 国投证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司河源分公司 | 公司南京分公司 | | 2025-12-01 | 002755 | 奥塞康 | 15.87 | 18.90 | 299.94 | 机构专用 | 华泰证券股份有限 | | | | | | | | | 公司面宣分公司 | 12月1日，奥赛康大宗交易成交63.1万股，成交额1001.4万元，占当日总成交额的6.24%，成交价15.87 元，较市场收盘价17.74元折价10.5 ...

Core Insights - The ITP drug treatment market in China is projected to grow, reaching 2.4 billion yuan in 2024, an increase of 200 million yuan from 2023, and is expected to reach approximately 2.8 billion yuan in 2025 [1][3][4] - Eltrombopag, a novel oral small molecule TPO receptor agonist, has shown excellent efficacy in treating ITP, significantly expanding treatment options for patients [1][4][7] - The sales of Eltrombopag in hospitals reached 376 million yuan in 2023, with an estimated 430 million yuan for the entire year of 2024 [1][4] ITP Drug Treatment Industry Pathway - ITP, or Immune Thrombocytopenic Purpura, is primarily treated with corticosteroids as the first-line therapy, while second-line treatments include platelet-stimulating drugs [2][4] - The incidence of ITP in adults in China is estimated at 5 to 10 per 100,000, with a projected 130,400 patients in 2024 [2][3] ITP Drug Treatment Industry Development Status - The ITP drug treatment market has been expanding, with a notable increase in treatment options due to ongoing research into the disease's pathophysiology [4][6] - The market is characterized by a growing number of patients and an increasing demand for effective treatments [2][3] ITP Drug Treatment Industry Chain - The upstream of the ITP drug treatment industry includes active pharmaceutical ingredients (APIs), chemical raw materials, and related equipment, while the midstream focuses on drug manufacturing [4][6] ITP Drug Treatment Competitive Landscape - Major companies in the domestic ITP drug market include Jiangsu Aosaikang Pharmaceutical, Jiangsu Hengrui Medicine, and Shenyang Sanofi Pharmaceutical, among others [2][6] - Several companies have received approval for Eltrombopag, indicating a competitive environment for generic versions of the drug [6][7] ITP Drug Treatment Development Trends - The treatment of ITP is moving towards targeted and precision medicine, with new therapies showing potential in regulating key immune nodes [7] - Future research may explore the combination of Eltrombopag with existing therapies to enhance treatment outcomes and achieve long-term remission for patients [7]

Core Insights - The stock price of Aosaikang has increased by 2.04% to 17.50 CNY per share as of November 26, with a total market capitalization of 16.243 billion CNY [1] - Aosaikang's stock has risen by 39.00% year-to-date, but has seen a decline of 29.86% over the past 60 days [1] - The company reported a revenue of 1.434 billion CNY for the first nine months of 2025, reflecting a year-on-year growth of 3.57%, while net profit increased by 75.81% to 223 million CNY [2] Financial Performance - Aosaikang has distributed a total of 721 million CNY in dividends since its A-share listing, with 111 million CNY distributed over the past three years [3] - The company has seen an increase in shareholder accounts by 8.50%, totaling 30,000 as of November 10 [2] Shareholder Structure - The top ten circulating shareholders include notable funds such as Yongying Medical Innovation Mixed Fund and Everbright Healthcare Industry Mixed Fund, with significant increases in their holdings [3] - The average number of circulating shares per shareholder has decreased by 7.83% to 30,917 shares [2]

Core Viewpoint - As of November 21, Osai Kang's stock price has decreased by 2.10%, with a current price of 16.78 CNY per share, reflecting a significant decline in recent trading days despite a year-to-date increase of 33.28% [1] Financial Performance - For the period from January to September 2025, Osai Kang achieved a revenue of 1.434 billion CNY, representing a year-on-year growth of 3.57%. The net profit attributable to shareholders was 223 million CNY, showing a substantial increase of 75.81% [2] Shareholder Information - As of November 10, the number of shareholders for Osai Kang reached 30,000, an increase of 8.50% from the previous period. The average number of circulating shares per person decreased by 7.83% to 30,917 shares [2] Dividend Distribution - Since its A-share listing, Osai Kang has distributed a total of 721 million CNY in dividends, with 111 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, among the top ten circulating shareholders, Yongying Medical Innovation Mixed Fund A increased its holdings by 9.27 million shares to 20.95 million shares, while new shareholders such as Yongying Ruixin Mixed Fund A and Yongying Stable Enhanced Bond A entered the top ten list [3]

Core Points - The company announced a share reduction plan by a major shareholder, Jiangsu Suyang Investment Industrial Co., Ltd. [2] - The reduction plan was disclosed on July 30, 2025, with a timeframe from August 20, 2025, to November 17, 2025 [2] - The shareholder planned to reduce up to 13,922,400 shares, representing 1.50% of the company's total share capital [2] - As of November 17, 2025, the shareholder completed the reduction, selling a total of 13,914,802 shares, which also accounted for 1.50% of the total share capital [2]

Core Points - The company, Aosaikang Pharmaceutical Co., Ltd., announced a share reduction by its shareholder Zhongyi Weiye Holdings Co., Ltd. [2] - Zhongyi Weiye reduced its holdings by 8,812,803 shares, representing 0.95% of the company's total share capital [2] - Prior to the reduction, Zhongyi Weiye held 120,192,033 shares, accounting for 12.95% of the total share capital; after the reduction, it holds 111,379,230 shares, which is 12.00% of the total [2]

Core Viewpoint - As of November 10, the number of shareholders for Aosaikang (002755) reached 30,020 [1] Company Summary - Aosaikang has reported a total of 30,020 shareholders as of November 10 [1]

Core Viewpoint - The company, Aosaikang (002755), emphasizes its commitment to focusing on its core business while ensuring compliance and steady development to enhance governance and core competitiveness, aiming to provide good returns for investors [1] Group 1: Business Focus - The company is continuously focusing on its main business operations [1] - It aims to enhance its governance level and core competitiveness [1] Group 2: Investor Communication - The company acknowledges that stock prices are influenced by market sentiment, industry conditions, and investment preferences [1] - It encourages investors to adopt a value investment approach and pay attention to the company's long-term value [1]

Core Points - The company Aosaikang (002755.SZ) announced the completion of a share reduction plan by Su Yang Investment, which has reduced its holdings by a total of 13,914,802 shares, accounting for 1.50% of the company's total share capital as of November 17, 2025 [1] Summary by Category - **Share Reduction Plan** - Su Yang Investment's share reduction plan has reached its deadline, with a total of 13,914,802 shares reduced [1] - The reduction was executed through centralized bidding and block trading methods [1] - The total shares reduced represent 1.50% of Aosaikang's total share capital [1]